We are live on ! Find out more
PC

Polar Capital Portfolio holdings

AUM $13.5B
1-Year Est. Return 55.9%
This Fund
S&P 500
This Quarter Est. Return
+1.33%
1 Year Est. Return
+55.9%
3 Year Est. Return
+127.44%
5 Year Est. Return
+269.08%
10 Year Est. Return
–
AUM
$4.77B
AUM Growth
+$70.4M
Cap. Flow
+$11M
Cap. Flow %
0.23%
Top 10 Hldgs %
22.27%
Holding
304
New
41
Increased
101
Reduced
84
Closed
35

Top Buys

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$47.7M
2
MRK icon
Merck
MRK
+$42.8M
3
AAPL icon
Apple
AAPL
+$34.5M
4
PEP icon
PepsiCo
PEP
+$31.1M
5
DOX icon
Amdocs
DOX
+$27M

Top Sells

Rank Stock Value
1
TWX
Time Warner Inc
TWX
+$41.8M
2
KO icon
Coca-Cola
KO
+$30M
3
COR icon
Cencora
COR
+$28.1M
4
MCD icon
McDonald's
MCD
+$27.7M
5
WBA
Walgreens Boots Alliance
WBA
+$25.2M

Sector Composition

Rank Sector Weight
1 Technology 25.24%
2 Financials 21.74%
3 Healthcare 19.4%
4 Communication Services 11.15%
5 Industrials 6.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CAH icon
226
Cardinal Health
CAH
$54.1B
$599K 0.01%
+8,000
New +$582K
ATRC icon
227
AtriCure
ATRC
$1.94B
$587K 0.01%
39,845
-777,350
-95% -$12.4M
SIVB
228
DELISTED
SVB Financial Group
SIVB
$495K 0.01%
+4,415
New +$490K
PB icon
229
Prosperity Bancshares
PB
$8.78B
$465K 0.01%
8,137
+3,466
+74% +$207K
CPHD
230
DELISTED
Cepheid Inc
CPHD
$445K 0.01%
10,103
+922
+10% +$38.9K
CMRX
231
DELISTED
Chimerix, Inc.
CMRX
$433K 0.01%
15,659
+2,255
+17% +$54.8K
ICPT
232
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$392K 0.01%
+1,655
New +$422K
INCY icon
233
Incyte
INCY
$25.4B
$364K 0.01%
+7,419
New +$372K
LAB icon
234
Standard BioTools
LAB
$303M
$361K 0.01%
14,734
+2,898
+24% +$81.5K
ARWR icon
235
Arrowhead Research
ARWR
$11.8B
$359K 0.01%
+24,300
New +$332K
AERI
236
DELISTED
Aerie Pharmaceuticals
AERI
$344K 0.01%
+16,613
New +$328K
CBST
237
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$329K 0.01%
+4,964
New +$326K
ALKS icon
238
Alkermes
ALKS
$8.54B
$327K 0.01%
7,623
-338,604
-98% -$15.2M
INFI
239
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$317K 0.01%
23,600
-1,634
-6% -$19.5K
DWCH
240
DELISTED
Datawatch Corp
DWCH
$315K 0.01%
30,775
-92,151
-75% -$1.17M
BMRN icon
241
BioMarin Pharmaceuticals
BMRN
$12.1B
$286K 0.01%
3,965
-2,299
-37% -$151K
EWBC icon
242
East-West Bancorp
EWBC
$18B
$268K 0.01%
+7,879
New +$273K
QIWI
243
DELISTED
QIWI PLC
QIWI
$268K 0.01%
8,470
– –
MET icon
244
MetLife
MET
$62.6B
$266K 0.01%
5,556
-2,837
-34% -$138K
TCBI icon
245
Texas Capital Bancshares
TCBI
$4.3B
$254K 0.01%
4,405
– –
ABUS icon
246
Arbutus Biopharma
ABUS
$869M
$239K 0.01%
+11,299
New +$184K
ACAD icon
247
Acadia Pharmaceuticals
ACAD
$4.41B
$213K ﹤0.01%
+8,609
New +$201K
OXFD
248
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$209K ﹤0.01%
13,681
+3,292
+32% +$50.4K
CLDX icon
249
Celldex Therapeutics
CLDX
$2.77B
$184K ﹤0.01%
+946
New +$206K
RNA
250
DELISTED
PROSENSA HLDGS N V ORD SHS (NLD)
RNA
$122K ﹤0.01%
+14,492
New +$137K
8 9
10
11 12

Similar funds

ECM
ETrade Capital Management Arlington, Virginia $5.37B AUM 10.84% 1-Year Est. Return
FAAS
First Allied Advisory Services San Diego, California $2.98B AUM 15.89% 1-Year Est. Return
WAM
Wealthspire Advisors (Maryland) Potomac, Maryland $2.84B AUM 10.91% 1-Year Est. Return
FS
Feinberg Stephen $2.61B AUM 15.12% 1-Year Est. Return
NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return
TI
TT International London, United Kingdom $1.94B AUM
VIM
Veritas Investment Management London, United Kingdom $1.65B AUM 25.54% 1-Year Est. Return
PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return

Polar Capital's Q3 2014 Portfolio in Review

As of Q3 2014, Polar Capital held 304 positions worth $4.77B, up 1.5% from $4.7B the previous quarter. Its ten largest holdings account for 22% of the portfolio.

Polar Capital's Q3 2014 filing shows 41 new, 101 increased, 84 reduced and 35 closed positions. Its largest new stake was Medtronic: 750,164 shares worth $46.5M. The largest sale was Time Warner Inc, an estimated $41.8M.

By sector, the portfolio is most concentrated in Technology at 25% of assets, down from 25% a quarter earlier, followed by Financials and Healthcare.

  • Polar Capital's largest Q3 2014 buy was Medtronic: 750,164 shares worth $46.5M.
  • Polar Capital added most to Merck in Q3 2014, an estimated $42.8M increase.
  • Polar Capital's biggest Q3 2014 reduction was Time Warner Inc, cutting an estimated $41.8M.
  • Polar Capital fully exited Coca-Cola in Q3 2014, selling an estimated $30M.
  • Polar Capital's ten largest holdings make up 22% of its $4.77B portfolio in Q3 2014.
  • Polar Capital opened 41 new positions and closed 35 in Q3 2014.
  • Polar Capital's portfolio value rose 1.5% quarter-over-quarter to $4.77B.

Based on Polar Capital's 13F filing for Q3 2014, filed 13 Nov 2014.